{"denoms":[{"counts":[{"groupId":"BG000","value":"32"}],"units":"Participants"}],"groups":[{"description":"Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nTrebananib: Given IV","id":"BG000","title":"Treatment (Trebananib)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"40 - 49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"50 - 59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"60 - 69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"70 - 79 years"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eligible and evaluable patients"}